|Articles|February 5, 2015
Accelovance Acquires European CRO
Accelovance, Inc. , a CRO therapeutically aligned in the areas of Oncology, Vaccines, and General Medicine; today announced it has acquired Altair Clinical, Ltd.
Advertisement
Accelovance, a therapeutically aligned CRO in the areas of oncology, vaccines, and general medicine; announced it has acquired Altair Clinical, a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. The acquisition expands Accelovance's existing US and Beijing, China offices to include Cambridge, UK, Moscow, Russia, and staff located throughout Europe including Central and Eastern Europe (CEE) and the Middle East and North Africa (MENA).
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose
2
Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology
3
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
4
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
5